LP
CTXR icon

LMR Partners’s Citius Pharmaceuticals CTXR Stock Holding History

LMR Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,357
Closed -$71K – 1140
2022
Q3 		$71K Hold
2,357
– – ﹤0.01% 1072
2022
Q2 		$54K Buy
+2,357
New +$64.6K ﹤0.01% 1154
2021
Q2 		– Sell
-2,558
Closed -$114K – 1168
2021
Q1 		$114K Buy
+2,558
New +$102K ﹤0.01% 849

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's CTXR Position: Q4 2022 in Review

LMR Partners sold out of Citius Pharmaceuticals (CTXR) in Q4 2022, closing a stake of 2,357 shares — an estimated $71K sold.

LMR Partners first reported a position in CTXR in Q1 2021 and held it in 3 quarters. The position peaked at $114K in Q1 2021. 54 funds tracked by Wall St. Rank hold CTXR as of Q4 2022.

  • LMR Partners reported no remaining Citius Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 2,357 Citius Pharmaceuticals shares in Q4 2022, an estimated $71K.
  • LMR Partners first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • LMR Partners's Citius Pharmaceuticals position peaked at $114K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.